News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

GlaxoSmithKline (GSK) Increases Stake in Response Genetics, Inc.


9/13/2012 6:50:14 AM

GlaxoSmithKline PLC (GSK.LN), the pharmaceutical company, announced Thursday that it bought five million newly issued shares of Response Genetics, Inc. (RGDX) at 1.10 dollars per share in cash, meaning that GSK now owns 15.2% of the expanded share capital of RGI. Transaction builds on the relationship GSK and RGI have been building in the diagnostics field of oncology and vaccines. RGI performs companion diagnostic tests and other related activities for GSK's immunotherapies and oncology pipeline candidates.

Read at Fox News
Read at Reuters
Read at News Release
Read at News Release


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES